Peter T. Lomedico

Peter T. Lomedico

Director
Industry Partners & Investments, JDRF T1D Fund

Peter Lomedico, Ph.D., joined JDRF in 2005 to lead the Industry Partnerships Program, an effort that supports the transfer of early-stage research to the commercial sector. Dr. Lomedico works closely with the research scientists to accelerate the development and delivery of diseasemodifying therapeutics and devices for people with type 1 diabetes (T1D) by engaging industry on JDRF research projects. A number of large pharmaceutical companies have entered into licensing and product development and commercialization agreements with JDRF-funded biotechnology companies, providing evidence that big pharma recognizes the commercial potential in T1D products. Dr. Lomedico has a diverse background in molecular biology, diabetes research, and drug discovery, with more than 25 years of pharmaceutical and biotechnology experience. Previously, he worked at NeoGenesis Pharmaceuticals, as vice president of strategic alliances, at CuraGen Corporation as vice president of discovery research, and at Genome Therapeutics Corporation as vice president of human genetics. In addition, Dr. Lomedico conducted genomics and drug discovery research in various positions at Hoffmann-LaRoche. Dr. Lomedico received his bachelor’s degree in biology from Villanova University and his doctorate in molecular biology from the University of Texas Health Science Center at Houston, and conducted research in the laboratory of Dr. Walter Gilbert at Harvard University with a postdoctoral research fellowship from JDRF

For more information, visit https://www.linkedin.com/in/peter-lomedico-b2695826/.